This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Check 5 Best Liquid Stocks for Impressive Returns
by Zacks Equity Research
Here are five top-ranked liquid stocks that investors can bank on for remarkable returns.
Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.
All You Need to Know About Alkermes (ALKS) Rating Upgrade to Strong Buy
by Zacks Equity Research
Alkermes (ALKS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3
by Zacks Equity Research
Alkermes (ALKS) beats estimates in the third quarter of 2019. Its proprietary products, especially Aristada, drive revenues.
Alkermes (ALKS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 80.00% and 1.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
Biogen Strengthens MS & SMA Portfolio as Competition Lurks
by Zacks Equity Research
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy
by Zacks Equity Research
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
Why Is Alkermes (ALKS) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
by Zacks Equity Research
Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.
Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
by Zacks Equity Research
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.
Alkermes (ALKS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 190.00% and 10.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Alkermes (ALKS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
by Zacks Equity Research
Key highlights of the past week include collaborations and other pipeline updates.
ALXN or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. ALKS: Which Stock Is the Better Value Option?
Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA
by Zacks Equity Research
Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.
CBM vs. ALKS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CBM vs. ALKS: Which Stock Is the Better Value Option?
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230
by Zacks Equity Research
Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
CBM vs. ALKS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CBM vs. ALKS: Which Stock Is the Better Value Option?
Biogen Reports Interim Phase III Data on Diroximel Fumarate
by Zacks Equity Research
Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression
by Zacks Equity Research
Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.
Why Is Alkermes (ALKS) Down 21% Since Last Earnings Report?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ALXN or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. ALKS: Which Stock Is the Better Value Option?
Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.